Acepodia Revenue and Competitors

Acepodia is using its proprietary bioconjugation technology to develop the next wave of off-the-shelf cell therapies for cancer. Our ACC™ platform simply and cost effectively links antibodies directly to immune cells, enhancing their tumor-killing ability without the need for genetic manipulation. Relative to other cellular immunotherapy approaches, ACC™ requires no genetic engineering of immune cells, and has a substantially improved dose-titration capability. Broadly tested with various existing antibodies, ACC™ is capable of arming effector cells with available antibodies. Acepodia production cell line, ACE-NK, is capable of allogeneic usage due to its lack of TCR (T-cell receptor) property. ACE-NK cells are super-charged with ACC™ to overcome suppressive tumor microenvironment. The lead program ACE1702 (anti-HER2 conjugated NK cells) has been validated both in vitro and in vivo, presenting promising treatment possibilities in a variety of cancer types. ACE1702 is planned to enter Phase 1 in 2019.